Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease

被引:36
|
作者
Ho, Jean K. [1 ]
Nation, Daniel A. [1 ]
机构
[1] Univ Southern Calif, Dept Psychol, 3620 South McClintock Ave, Los Angeles, CA 90089 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
Alzheimer's disease; Amyloid beta; Tau; Biomarkers; Cognition; Memory; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RISK-FACTOR; DECLINE; PATHOPHYSIOLOGY; RECOMMENDATIONS; NEURODEGENERATION; INDIVIDUALS;
D O I
10.1017/S135561771800022X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The present study investigated the independent and synergistic effects of amyloid beta (A beta(1-42)) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. Methods: Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N= 518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (A beta-Ptau-, A beta+Ptau-, A beta-Ptau+, A beta+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. Results: The A beta+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the A beta-Ptau+ and A beta-Ptau- groups. The A beta+Ptau- group fell between the A beta+Ptau+ participants and the A beta-Ptau- and A beta-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The A beta-Ptau+ group performed worse than A beta-Ptau- participants on processing speed. Over 36-month follow-up, the A beta+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. Conclusions: Cognitively normal older adults with both A beta and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with A beta pathology alone showed worse attention and executive function compared to biomarker negative participants.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 50 条
  • [21] Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease
    Baker, Jenalle E.
    Lim, Yen Ying
    Jaeger, Judith
    Ames, David
    Lautenschlager, Nicola T.
    Robertson, Joanne
    Pietrzak, Robert H.
    Snyder, Peter J.
    Villemagne, Victor L.
    Rowe, Christopher C.
    Masters, Colin L.
    Maruff, Paul
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 65 (03) : 977 - 988
  • [22] Progress in Alzheimer's disease
    Galimberti, Daniela
    Scarpini, Elio
    JOURNAL OF NEUROLOGY, 2012, 259 (02) : 201 - 211
  • [23] Subjective cognitive decline: preclinical manifestation of Alzheimer's disease
    Lin, Yan
    Shan, Pei-Yan
    Jiang, Wen-Jing
    Sheng, Can
    Ma, Lin
    NEUROLOGICAL SCIENCES, 2019, 40 (01) : 41 - 49
  • [24] Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective
    Watermeyer, Tamlyn
    Calia, Clara
    JOURNAL OF GLOBAL HEALTH, 2019, 9 (01)
  • [25] Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
    Allegri, Ricardo F.
    Chrem Mendez, Patricio
    Calandri, Ismael
    Cohen, Gabriela
    Eugenia Martin, Maria
    Julieta Russo, Maria
    Crivelli, Lucia
    Pertierra, Lucia
    Tapajoz, Fernanda
    Florencia Clarens, Maria
    Campos, Jorge
    Nahas, Federico E.
    Vazquez, Silvia
    Surace, Ezequiel
    Sevlever, Gustavo
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [26] Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review
    Garcia-Escobar, Greta
    Manero, Rosa Maria
    Fernandez-Lebrero, Aida
    Ois, Angel
    Navalpotro-Gomez, Irene
    Puente-Periz, Victor
    Contador-Munana, Jose
    Estragues-Gazquez, Isabel
    Puig-Pijoan, Albert
    Jimenez-Balado, Joan
    BIOMOLECULES, 2024, 14 (01)
  • [27] Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease
    Arnáiz, E
    Almkvist, O
    ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 : 34 - 41
  • [28] Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study
    Burnham, Samantha C.
    Bourgeat, Pierrick
    Dore, Vincent
    Savage, Greg
    Brown, Belinda
    Laws, Simon
    Maruff, Paul
    Salvado, Olivier
    Ames, David
    Martins, Ralph N.
    Masters, Colin L.
    Rowe, Christopher C.
    Villemagne, Victor L.
    LANCET NEUROLOGY, 2016, 15 (10) : 1044 - 1053
  • [29] Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia
    Tan, Meng-Shan
    Ji, Xi
    Li, Jie-Qiong
    Xu, Wei
    Wang, Hui-Fu
    Tan, Chen-Chen
    Dong, Qiang
    Zuo, Chuan-Tao
    Tan, Lan
    Suckling, John
    Yu, Jin-Tai
    ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
  • [30] Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
    Vos, Stephanie J. B.
    Xiong, Chengjie
    Visser, Pieter Jelle
    Jasielec, Mateusz S.
    Hassenstab, Jason
    Grant, Elizabeth A.
    Cairns, Nigel J.
    Morris, John C.
    Holtzman, David M.
    Fagan, Anne M.
    LANCET NEUROLOGY, 2013, 12 (10) : 957 - 965